<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627545</url>
  </required_header>
  <id_info>
    <org_study_id>2010-ABU-010-ND</org_study_id>
    <nct_id>NCT04627545</nct_id>
  </id_info>
  <brief_title>Co-incubation of Oocytes With Sperm: Defining the Optimal Incubation Time</brief_title>
  <official_title>Co-incubation of Oocytes With Sperm: Defining the Optimal Incubation Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ART Fertility Clinics LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ART Fertility Clinics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current pilot study aims to evaluate the fertilization rates between sibling oocytes&#xD;
      subjected to short incubation (2h) versus overnight incubation (16-20h). As secondary&#xD;
      objectives, the abnormal fertilization, embryo development, blastocyst biopsy and euploid&#xD;
      rates will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients for whom at least 6 cumulus oocytes complexes (COCs) are assigned to IVF, with&#xD;
      normal sperm parameters, are eligible for the study. An electronically generated&#xD;
      randomization list will allocate the first half of the oocytes to one arm and the other half&#xD;
      of the oocytes to the second arm. In case an odd number of oocytes will be inseminated, one&#xD;
      extra oocyte will be allocated to the first arm. In this prospective observational pilot&#xD;
      study, the fertilization potential of 40 patients will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Oocytes of one patient will be evenly and randomly distributed between two timings of exposure to sperm: 2h exposure versus overnight exposure (16-20h)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normal fertilization rate</measure>
    <time_frame>2 days</time_frame>
    <description>presence of two pronuclei per inseminated oocyte</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of COCs assigned to each group</measure>
    <time_frame>2 days</time_frame>
    <description>number of oocytes, per patient, assigned to each exposure group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maturation rate</measure>
    <time_frame>2 days</time_frame>
    <description>number of mature oocytes obtained in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization</measure>
    <time_frame>3 days</time_frame>
    <description>Number of abnormally fertilized oocytes and failed fertilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fertilization failure</measure>
    <time_frame>3 days</time_frame>
    <description>Number of cycles with complete fertilization failure (in one arm or in both arms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality on day 3</measure>
    <time_frame>5 days</time_frame>
    <description>defined by the Istanbul consensus (Alpha Scientists, 2011) The number of blastomeres and their division pattern, fragmentation, presence of compaction, vacuoles, granulation and nuclei will divide the embryos into 3 categories: good, fair or poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality on day 5</measure>
    <time_frame>8 days</time_frame>
    <description>defined by a modified model of Gardner and Schoolcraft,1999</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blastulation rate I</measure>
    <time_frame>8 days</time_frame>
    <description>number of embryos reaching at least the BL1 stage/ number of oocytes assigned to that group: defined by a 1 (yes, the embryo is blastulating) or 0 (no, the embryo is not blastulating)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blastulation rate II</measure>
    <time_frame>8 days</time_frame>
    <description>number of embryos reaching at least the BL1 stage/ number of mature oocytes in that group: defined by a 1 (yes, the embryo is blastulating) or 0 (no, the embryo is not blastulating)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilization rate</measure>
    <time_frame>8 days</time_frame>
    <description>number of embryos that can be used for the patient (=number of embryos that can be biopsied)/number of oocytes assigned to the group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of trophectoderm biopsy</measure>
    <time_frame>8 days</time_frame>
    <description>Day at which the blastocyst reaches sufficient expansion to perform biopsy of trophectoderm cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euploid rate</measure>
    <time_frame>8 days</time_frame>
    <description>Number of genetically normal embryos per total number of blastocysts biopsied, stratified per day of biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphokinetic parameters</measure>
    <time_frame>10 days</time_frame>
    <description>As embryos will be monitored in a time lapse imaging system, morphokinetic parameters will be compared between both exposure arms: o t2: the timing to two cells&#xD;
t3: the timing to three cells&#xD;
t4: the timing to four cells&#xD;
t5: the timing to five cells&#xD;
t8: the timing to eight cells&#xD;
SC: starting to compact&#xD;
M: the timing to morula&#xD;
SB: starting to blastulate&#xD;
B: reaching a BL3 according to Gardner and Schoolcraft, 1999&#xD;
F: reaching a BL4 according to Gardner and Schoolcraft, 1999&#xD;
cc2: t3-t2&#xD;
s2: t4-t3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome</measure>
    <time_frame>60 days</time_frame>
    <description>dichotomous variable defined by the presence of βhCG test of &gt; 15IU 12-15 days after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy</measure>
    <time_frame>70 days</time_frame>
    <description>dichotomous variable defined as a pregnancy in which the hCG levels start do decrease after 1 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>80 days</time_frame>
    <description>defined by the number of gestational sacs/number of embryos transferred&#xD;
• Clinical pregnancy (yes or no) defined by the ultrasonographic visualization of one or more gestational sacs, including ectopic pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy Fetal Heart beat positive</measure>
    <time_frame>80 days</time_frame>
    <description>dichotomous variable defined by the ultrasonographic visualization of one or more gestational sacs, with fetal heart beat at 7 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>IVF: 2h exposure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of a patients' oocytes will be subjected to 2h exposure to sperm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVF: overnight exposure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of a patients' oocytes will be subjected to overnight incubation with sperm (=usual practice).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2h exposure to sperm for IVF</intervention_name>
    <description>Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination</description>
    <arm_group_label>IVF: 2h exposure</arm_group_label>
    <other_name>short exposure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>overnight exposure to sperm for IVF</intervention_name>
    <description>Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination</description>
    <arm_group_label>IVF: overnight exposure</arm_group_label>
    <other_name>long exposure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sperm parameters&#xD;
&#xD;
               -  Sperm concentration before capacitation: &gt;15 million per ml (WHO) Total motility&#xD;
                  (PR+NP %): &gt;40 (WHO) Progressive motility (PR %):&gt;32 (WHO)&#xD;
&#xD;
               -  Sperm concentration after capacitation: &gt;0.6 million per ml (not WHO defined)&#xD;
                  Progressive motility (PR %):&gt;65 (WHO)&#xD;
&#xD;
          -  ≥6 COCs assigned to IVF&#xD;
&#xD;
          -  BMI ≤35 kg/m2&#xD;
&#xD;
          -  Female age 18 to ≤ 43 years&#xD;
&#xD;
          -  All ovarian stimulation protocols&#xD;
&#xD;
          -  Fresh ejaculates&#xD;
&#xD;
          -  Abstinence duration 2-5 days&#xD;
&#xD;
          -  Presence or absence of sperm morphology data: as we do not have a diagnostic sperm&#xD;
             analysis for all patients, the presence or absence of &gt;4% normal morphology (WHO) will&#xD;
             not be taken into account, even with known low (&lt;4%) normal morphology&#xD;
&#xD;
          -  Couples requesting Preimplantation Genetic Testing for Aneuploidies&#xD;
&#xD;
          -  Arab population&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If the volume to be added after IVF is insufficient to perform IVF on all needed&#xD;
             oocytes&#xD;
&#xD;
          -  Presence of &gt;1 million per ml round cells in the ejaculate&#xD;
&#xD;
          -  If a couple's previous cycle was included in the study&#xD;
&#xD;
          -  Previous history of fertilization failure&#xD;
&#xD;
          -  Globozoospermia&#xD;
&#xD;
          -  PCO according to the Rotterdam criteria&#xD;
&#xD;
          -  Progesterone &gt;1.5 ng/ml on the day of trigger&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients seeking fertility treatment</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neelke De Munck, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ART Fertility Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neelke De Munck, PhD</last_name>
    <phone>+971501982760</phone>
    <email>Neelke.demunck@artfertilityclinics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Lawrenz, PhD, MD</last_name>
    <phone>+971526500757</phone>
    <email>Barbara.lawrenz@artfertilityclinics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ART Fertility Clinics</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neelke De Munck, PhD</last_name>
      <phone>+971501982760</phone>
      <email>Neelke.demunck@artfertilityclinics.com</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Lawrenz, PhD, MD</last_name>
      <phone>+971526500757</phone>
      <email>Barbara.Lawrenz@artfertilityclinics.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The principal investigator will gather all data for the study and prepare the database for the statistician, who will be blinded for patient information.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

